Gelteq (NASDAQ:GELS – Get Free Report) and Corcept Therapeutics (NASDAQ:CORT – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.
Institutional & Insider Ownership
93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.5% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Gelteq and Corcept Therapeutics”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Gelteq | N/A | N/A | N/A | N/A | N/A |
Corcept Therapeutics | $675.04 million | 8.75 | $106.14 million | $1.24 | 45.17 |
Profitability
This table compares Gelteq and Corcept Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Gelteq | N/A | N/A | N/A |
Corcept Therapeutics | 22.35% | 24.54% | 20.24% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Gelteq and Corcept Therapeutics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Gelteq | 0 | 0 | 0 | 0 | 0.00 |
Corcept Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
Corcept Therapeutics has a consensus price target of $99.75, suggesting a potential upside of 78.09%. Given Corcept Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Gelteq.
Summary
Corcept Therapeutics beats Gelteq on 9 of the 9 factors compared between the two stocks.
About Gelteq
Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Receive News & Ratings for Gelteq Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelteq and related companies with MarketBeat.com's FREE daily email newsletter.